Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Prostate (Late Stage^), 2017-2021

All Races (includes Hispanic), Male, All Ages

Sorted by Percentlate

State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late ascending
US (SEER+NPCR) 1 24.7 (24.6, 24.8) N/A 48,295 21.5
Vermont 6 31.8 (29.5, 34.3) 2 (1, 13) 150 28.8
Hawaii 3 27.3 (25.8, 28.8) 17 (7, 28) 268 26.7
Washington 5 28.7 (28.0, 29.5) 11 (6, 16) 1,288 26.7
Minnesota 6 31.7 (30.8, 32.5) 3 (1, 6) 1,113 26.5
Oregon 6 26.2 (25.3, 27.1) 20 (15, 29) 723 26.3
California 3 25.3 (25.0, 25.6) 28 (22, 30) 5,488 25.3
Colorado 6 25.8 (25.0, 26.7) 22 (16, 30) 814 24.8
North Dakota 6 30.7 (28.4, 33.1) 5 (1, 16) 142 24.8
Wisconsin 6 31.1 (30.3, 31.9) 4 (1, 7) 1,199 24.6
Maine 6 25.9 (24.5, 27.4) 21 (13, 32) 270 24.1
Missouri 6 23.5 (22.8, 24.2) 33 (30, 39) 923 24.1
Iowa 3 30.3 (29.3, 31.5) 6 (1, 11) 621 23.9
Nebraska 6 29.1 (27.7, 30.5) 9 (3, 17) 347 23.9
Arizona 6 19.0 (18.4, 19.6) 48 (44, 50) 865 23.6
Illinois 3 28.1 (27.5, 28.6) 13 (9, 17) 2,150 23.6
New Hampshire 6 27.9 (26.3, 29.4) 15 (6, 24) 272 23.1
District of Columbia 6 32.0 (29.1, 35.0) 1 (1, 15) 96 22.9
Pennsylvania 6 25.3 (24.8, 25.8) 27 (20, 31) 2,213 22.8
Idaho 3 27.7 (26.3, 29.2) 16 (6, 24) 304 22.5
South Dakota 6 28.5 (26.5, 30.6) 12 (2, 25) 161 22.4
New Mexico 3 19.4 (18.4, 20.5) 46 (43, 50) 268 22.2
Connecticut 3 29.1 (28.1, 30.1) 8 (4, 16) 669 21.8
Rhode Island 6 25.3 (23.6, 27.0) 29 (14, 37) 178 21.8
Montana 6 29.2 (27.5, 31.0) 7 (2, 19) 229 21.7
Ohio 6 25.8 (25.2, 26.3) 23 (18, 29) 1,954 21.6
Michigan 6 24.7 (24.1, 25.2) 30 (24, 33) 1,634 21.3
Alaska 6 22.8 (20.5, 25.3) 37 (19, 46) 87 21.0
Texas 3 22.6 (22.2, 22.9) 39 (34, 42) 3,251 20.8
Louisiana 3 29.1 (28.1, 30.0) 10 (5, 16) 817 20.6
Utah 3 25.4 (24.2, 26.7) 25 (16, 33) 364 20.5
Florida 6 21.1 (20.7, 21.4) 43 (41, 44) 3,238 20.3
Virginia 6 22.3 (21.7, 22.9) 40 (34, 42) 1,125 20.2
New York 3 26.9 (26.4, 27.3) 18 (15, 21) 3,275 20.1
South Carolina 6 22.6 (21.9, 23.4) 38 (32, 42) 749 19.9
Tennessee 6 23.0 (22.3, 23.7) 35 (31, 41) 980 19.9
Oklahoma 6 20.5 (19.7, 21.3) 44 (41, 47) 480 19.7
Kentucky 3 22.9 (22.1, 23.8) 36 (31, 42) 624 19.4
Mississippi 6 26.2 (25.2, 27.4) 19 (14, 30) 467 19.3
North Carolina 6 25.7 (25.1, 26.3) 24 (18, 30) 1,591 19.3
West Virginia 6 19.7 (18.6, 20.9) 45 (42, 50) 253 18.9
Nevada 6 18.1 (17.3, 19.1) 50 (45, 50) 341 18.8
Kansas 6 22.2 (21.3, 23.3) 41 (32, 44) 397 18.4
Arkansas 6 19.0 (18.1, 20.0) 47 (44, 50) 358 18.3
Wyoming 6 21.3 (19.2, 23.5) 42 (30, 50) 84 18.2
Georgia 3 25.3 (24.7, 25.9) 26 (19, 31) 1,451 17.9
Delaware 6 23.8 (22.1, 25.6) 32 (19, 42) 158 17.5
Maryland 6 23.3 (22.6, 24.1) 34 (30, 41) 849 16.8
New Jersey 3 24.0 (23.4, 24.6) 31 (28, 36) 1,358 16.7
Alabama 6 18.2 (17.6, 18.9) 49 (46, 50) 582 15.8
Puerto Rico 6 14.8 (14.0, 15.5) N/A 303 10.4
Indiana 6
data not available
N/A
data not available
data not available
Notes:
Created by statecancerprofiles.cancer.gov on 12/11/2024 5:07 pm.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.
1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
3 Source: SEER November 2023 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2023 submission).

Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top